Which has preferable earnings and valuation, EVO or QSI?

Quantum-Si has lower revenue, but higher earnings than Evotec. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Evotec $891.97M 0.72 -$117.12M N/A N/A Quantum-Si $2.44M 67.28 -$101.34M -$0.46 N/A

Is EVO or QSI more profitable?

Evotec has a net margin of -26.20% compared to Quantum-Si's net margin of -6,138.26%. Evotec's return on equity of -24.93% beat Quantum-Si's return on equity. Company Net Margins Return on Equity Return on Assets Evotec -26.20% -24.93% -11.35% Quantum-Si -6,138.26% -47.12% -43.18%

Does the media favor EVO or QSI?

In the previous week, Evotec had 8 more articles in the media than Quantum-Si. MarketBeat recorded 10 mentions for Evotec and 2 mentions for Quantum-Si. Quantum-Si's average media sentiment score of 0.00 beat Evotec's score of -0.10 indicating that Quantum-Si is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evotec 0 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Quantum-Si 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, OABI or QSI?

OmniAb has higher revenue and earnings than Quantum-Si. OmniAb is trading at a lower price-to-earnings ratio than Quantum-Si, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OmniAb $18.67M 31.10 -$64.78M -$0.36 N/A Quantum-Si $2.44M 67.28 -$101.34M -$0.46 N/A

Is OABI or QSI more profitable?

OmniAb has a net margin of -115.12% compared to Quantum-Si's net margin of -6,138.26%. OmniAb's return on equity of -16.59% beat Quantum-Si's return on equity. Company Net Margins Return on Equity Return on Assets OmniAb -115.12% -16.59% -14.82% Quantum-Si -6,138.26% -47.12% -43.18%

Does the media favor OABI or QSI?

In the previous week, Quantum-Si had 1 more articles in the media than OmniAb. MarketBeat recorded 2 mentions for Quantum-Si and 1 mentions for OmniAb. OmniAb's average media sentiment score of 0.69 beat Quantum-Si's score of 0.00 indicating that OmniAb is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OmniAb 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Quantum-Si 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer CTKB or QSI?

In the previous week, Cytek Biosciences had 3 more articles in the media than Quantum-Si. MarketBeat recorded 5 mentions for Cytek Biosciences and 2 mentions for Quantum-Si. Cytek Biosciences' average media sentiment score of 0.19 beat Quantum-Si's score of 0.00 indicating that Cytek Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytek Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Quantum-Si 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is DNA or QSI more profitable?

Ginkgo Bioworks has a net margin of -259.96% compared to Quantum-Si's net margin of -6,138.26%. Quantum-Si's return on equity of -47.12% beat Ginkgo Bioworks' return on equity. Company Net Margins Return on Equity Return on Assets Ginkgo Bioworks -259.96% -60.27% -26.88% Quantum-Si -6,138.26% -47.12% -43.18%

Does the media prefer DNA or QSI?

In the previous week, Ginkgo Bioworks had 4 more articles in the media than Quantum-Si. MarketBeat recorded 6 mentions for Ginkgo Bioworks and 2 mentions for Quantum-Si. Ginkgo Bioworks' average media sentiment score of 0.03 beat Quantum-Si's score of 0.00 indicating that Ginkgo Bioworks is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ginkgo Bioworks 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Quantum-Si 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to QSI or PACB?

In the previous week, Pacific Biosciences of California had 1 more articles in the media than Quantum-Si. MarketBeat recorded 3 mentions for Pacific Biosciences of California and 2 mentions for Quantum-Si. Pacific Biosciences of California's average media sentiment score of 0.32 beat Quantum-Si's score of 0.00 indicating that Pacific Biosciences of California is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quantum-Si 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pacific Biosciences of California 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Quantum-Si (QSI) Competitors

$0.75 -0.01 (-1.32%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$0.75 +0.00 (+0.27%)

As of 07:20 AM Eastern

Compare

QSI vs. EVO, OABI, CTKB, DNA, and PACB

Should you buy Quantum-Si stock or one of its competitors? Quantum-Si's main competitors and comparable companies include Evotec (EVO), OmniAb (OABI), Cytek Biosciences (CTKB), Ginkgo Bioworks (DNA), and Pacific Biosciences of California (PACB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Quantum-Si compare to Evotec?

Evotec (NASDAQ:EVO) and Quantum-Si (NASDAQ:QSI) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and media sentiment.

Evotec currently has a consensus price target of $3.00, suggesting a potential upside of 65.75%. Quantum-Si has a consensus price target of $1.00, suggesting a potential upside of 33.33%. Given Evotec's higher probable upside, analysts plainly believe Evotec is more favorable than Quantum-Si.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evotec	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Quantum-Si	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Evotec has a beta of 1.92, indicating that its share price is 92% more volatile than the broader market. Comparatively, Quantum-Si has a beta of 3.25, indicating that its share price is 225% more volatile than the broader market.

Quantum-Si has lower revenue, but higher earnings than Evotec.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evotec	$891.97M	0.72	-$117.12M	N/A	N/A
Quantum-Si	$2.44M	67.28	-$101.34M	-$0.46	N/A

Evotec has a net margin of -26.20% compared to Quantum-Si's net margin of -6,138.26%. Evotec's return on equity of -24.93% beat Quantum-Si's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evotec	-26.20%	-24.93%	-11.35%
Quantum-Si	-6,138.26%	-47.12%	-43.18%

5.8% of Evotec shares are held by institutional investors. Comparatively, 39.9% of Quantum-Si shares are held by institutional investors. 1.0% of Evotec shares are held by insiders. Comparatively, 22.0% of Quantum-Si shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Evotec had 8 more articles in the media than Quantum-Si. MarketBeat recorded 10 mentions for Evotec and 2 mentions for Quantum-Si. Quantum-Si's average media sentiment score of 0.00 beat Evotec's score of -0.10 indicating that Quantum-Si is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evotec	0 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Quantum-Si	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Evotec and Quantum-Si tied by winning 6 of the 12 factors compared between the two stocks.

How does Quantum-Si compare to OmniAb?

OmniAb (NASDAQ:OABI) and Quantum-Si (NASDAQ:QSI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations and valuation.

OmniAb has a net margin of -115.12% compared to Quantum-Si's net margin of -6,138.26%. OmniAb's return on equity of -16.59% beat Quantum-Si's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OmniAb	-115.12%	-16.59%	-14.82%
Quantum-Si	-6,138.26%	-47.12%	-43.18%

OmniAb presently has a consensus target price of $11.00, suggesting a potential upside of 174.31%. Quantum-Si has a consensus target price of $1.00, suggesting a potential upside of 33.33%. Given OmniAb's stronger consensus rating and higher possible upside, analysts clearly believe OmniAb is more favorable than Quantum-Si.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OmniAb	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Quantum-Si	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Quantum-Si had 1 more articles in the media than OmniAb. MarketBeat recorded 2 mentions for Quantum-Si and 1 mentions for OmniAb. OmniAb's average media sentiment score of 0.69 beat Quantum-Si's score of 0.00 indicating that OmniAb is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OmniAb	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Quantum-Si	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

OmniAb has a beta of 0.62, indicating that its stock price is 38% less volatile than the broader market. Comparatively, Quantum-Si has a beta of 3.25, indicating that its stock price is 225% more volatile than the broader market.

OmniAb has higher revenue and earnings than Quantum-Si. OmniAb is trading at a lower price-to-earnings ratio than Quantum-Si, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OmniAb	$18.67M	31.10	-$64.78M	-$0.36	N/A
Quantum-Si	$2.44M	67.28	-$101.34M	-$0.46	N/A

72.1% of OmniAb shares are held by institutional investors. Comparatively, 39.9% of Quantum-Si shares are held by institutional investors. 9.8% of OmniAb shares are held by insiders. Comparatively, 22.0% of Quantum-Si shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

OmniAb beats Quantum-Si on 11 of the 16 factors compared between the two stocks.

How does Quantum-Si compare to Cytek Biosciences?

Cytek Biosciences (NASDAQ:CTKB) and Quantum-Si (NASDAQ:QSI) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, media sentiment, risk, analyst recommendations, institutional ownership and dividends.

Cytek Biosciences has a beta of 1.18, meaning that its stock price is 18% more volatile than the broader market. Comparatively, Quantum-Si has a beta of 3.25, meaning that its stock price is 225% more volatile than the broader market.

Cytek Biosciences currently has a consensus price target of $5.56, suggesting a potential upside of 17.60%. Quantum-Si has a consensus price target of $1.00, suggesting a potential upside of 33.33%. Given Quantum-Si's higher possible upside, analysts clearly believe Quantum-Si is more favorable than Cytek Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Quantum-Si	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Cytek Biosciences has higher revenue and earnings than Quantum-Si. Cytek Biosciences is trading at a lower price-to-earnings ratio than Quantum-Si, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytek Biosciences	$201.49M	3.05	-$66.54M	-$0.62	N/A
Quantum-Si	$2.44M	67.28	-$101.34M	-$0.46	N/A

Cytek Biosciences has a net margin of -38.98% compared to Quantum-Si's net margin of -6,138.26%. Cytek Biosciences' return on equity of -12.40% beat Quantum-Si's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytek Biosciences	-38.98%	-12.40%	-9.17%
Quantum-Si	-6,138.26%	-47.12%	-43.18%

In the previous week, Cytek Biosciences had 3 more articles in the media than Quantum-Si. MarketBeat recorded 5 mentions for Cytek Biosciences and 2 mentions for Quantum-Si. Cytek Biosciences' average media sentiment score of 0.19 beat Quantum-Si's score of 0.00 indicating that Cytek Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytek Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Quantum-Si	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

69.5% of Cytek Biosciences shares are held by institutional investors. Comparatively, 39.9% of Quantum-Si shares are held by institutional investors. 10.4% of Cytek Biosciences shares are held by insiders. Comparatively, 22.0% of Quantum-Si shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Cytek Biosciences beats Quantum-Si on 10 of the 16 factors compared between the two stocks.

How does Quantum-Si compare to Ginkgo Bioworks?

Ginkgo Bioworks (NYSE:DNA) and Quantum-Si (NASDAQ:QSI) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation, profitability and media sentiment.

Ginkgo Bioworks has a net margin of -259.96% compared to Quantum-Si's net margin of -6,138.26%. Quantum-Si's return on equity of -47.12% beat Ginkgo Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ginkgo Bioworks	-259.96%	-60.27%	-26.88%
Quantum-Si	-6,138.26%	-47.12%	-43.18%

In the previous week, Ginkgo Bioworks had 4 more articles in the media than Quantum-Si. MarketBeat recorded 6 mentions for Ginkgo Bioworks and 2 mentions for Quantum-Si. Ginkgo Bioworks' average media sentiment score of 0.03 beat Quantum-Si's score of 0.00 indicating that Ginkgo Bioworks is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ginkgo Bioworks	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Quantum-Si	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Quantum-Si has lower revenue, but higher earnings than Ginkgo Bioworks. Quantum-Si is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ginkgo Bioworks	$170.15M	2.68	-$312.76M	-$5.01	N/A
Quantum-Si	$2.44M	67.28	-$101.34M	-$0.46	N/A

Ginkgo Bioworks currently has a consensus price target of $6.33, indicating a potential downside of 6.53%. Quantum-Si has a consensus price target of $1.00, indicating a potential upside of 33.33%. Given Quantum-Si's stronger consensus rating and higher possible upside, analysts clearly believe Quantum-Si is more favorable than Ginkgo Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ginkgo Bioworks	2 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Quantum-Si	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Ginkgo Bioworks has a beta of 1.76, meaning that its share price is 76% more volatile than the broader market. Comparatively, Quantum-Si has a beta of 3.25, meaning that its share price is 225% more volatile than the broader market.

78.6% of Ginkgo Bioworks shares are owned by institutional investors. Comparatively, 39.9% of Quantum-Si shares are owned by institutional investors. 12.7% of Ginkgo Bioworks shares are owned by insiders. Comparatively, 22.0% of Quantum-Si shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Quantum-Si beats Ginkgo Bioworks on 9 of the 16 factors compared between the two stocks.

How does Quantum-Si compare to Pacific Biosciences of California?

Quantum-Si (NASDAQ:QSI) and Pacific Biosciences of California (NASDAQ:PACB) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, earnings, dividends and analyst recommendations.

Quantum-Si has higher earnings, but lower revenue than Pacific Biosciences of California. Pacific Biosciences of California is trading at a lower price-to-earnings ratio than Quantum-Si, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quantum-Si	$2.44M	67.28	-$101.34M	-$0.46	N/A
Pacific Biosciences of California	$160.01M	2.51	-$546.38M	-$0.43	N/A

Quantum-Si presently has a consensus price target of $1.00, indicating a potential upside of 33.33%. Pacific Biosciences of California has a consensus price target of $1.71, indicating a potential upside of 32.75%. Given Quantum-Si's stronger consensus rating and higher probable upside, equities analysts clearly believe Quantum-Si is more favorable than Pacific Biosciences of California.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quantum-Si	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Pacific Biosciences of California	2 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.83

39.9% of Quantum-Si shares are owned by institutional investors. 22.0% of Quantum-Si shares are owned by company insiders. Comparatively, 3.7% of Pacific Biosciences of California shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Quantum-Si has a beta of 3.25, suggesting that its stock price is 225% more volatile than the broader market. Comparatively, Pacific Biosciences of California has a beta of 2.31, suggesting that its stock price is 131% more volatile than the broader market.

In the previous week, Pacific Biosciences of California had 1 more articles in the media than Quantum-Si. MarketBeat recorded 3 mentions for Pacific Biosciences of California and 2 mentions for Quantum-Si. Pacific Biosciences of California's average media sentiment score of 0.32 beat Quantum-Si's score of 0.00 indicating that Pacific Biosciences of California is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quantum-Si	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pacific Biosciences of California	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Pacific Biosciences of California has a net margin of -82.49% compared to Quantum-Si's net margin of -6,138.26%. Quantum-Si's return on equity of -47.12% beat Pacific Biosciences of California's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quantum-Si	-6,138.26%	-47.12%	-43.18%
Pacific Biosciences of California	-82.49%	-5,752.12%	-19.52%

Summary

Quantum-Si beats Pacific Biosciences of California on 9 of the 15 factors compared between the two stocks.

Get Quantum-Si News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QSI vs. The Competition

Export

Metric	Quantum-Si	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$166.35M	$9.79B	$7.22B	$12.88B
Dividend Yield	N/A	1.47%	2.55%	9.95%
P/E Ratio	-1.63	65.14	271.78	25.29
Price / Sales	67.28	109.19	712.57	118.14
Price / Cash	N/A	26.46	77.55	52.32
Price / Book	0.74	5.25	10.50	6.26
Net Income	-$101.34M	$56.67B	$3.48B	$357.86M
7 Day Performance	-1.45%	-1.22%	-1.17%	-0.59%
1 Month Performance	-5.08%	0.16%	2.00%	-1.07%
1 Year Performance	-33.04%	26.07%	21.90%	11.31%

Quantum-Si Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QSI Quantum-Si	2.5368 of 5 stars	$0.75 -1.3%	$1.00 +33.3%	-34.8%	$166.35M	$2.44M	N/A	150	News Coverage
EVO Evotec	2.5254 of 5 stars	$1.88 -1.6%	$3.00 +59.6%	-47.4%	$679.61M	$891.97M	N/A	4,553
OABI OmniAb	2.2727 of 5 stars	$4.38 -2.0%	$11.00 +151.1%	+155.4%	$647.18M	$18.67M	N/A	7
CTKB Cytek Biosciences	1.7568 of 5 stars	$4.78 +2.1%	$5.56 +16.4%	+20.4%	$608.32M	$201.49M	N/A	500	News Coverage Positive News
DNA Ginkgo Bioworks	1.3751 of 5 stars	$6.81 -2.2%	$7.00 +2.8%	-36.9%	$468.69M	$170.15M	N/A	640	Analyst Forecast Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QSI) was last updated on 9/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Quantum-Si (QSI) Competitors

QSI vs. EVO, OABI, CTKB, DNA, and PACB

How does Quantum-Si compare to Evotec?

Summary

How does Quantum-Si compare to OmniAb?

Summary

How does Quantum-Si compare to Cytek Biosciences?

Summary

How does Quantum-Si compare to Ginkgo Bioworks?

Summary

How does Quantum-Si compare to Pacific Biosciences of California?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QSI vs. The Competition

Quantum-Si Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Quantum-Si (QSI) Competitors

QSI vs. EVO, OABI, CTKB, DNA, and PACB

How does Quantum-Si compare to Evotec?

Do analysts recommend EVO or QSI?

Which has more volatility & risk, EVO or QSI?

Which has preferable earnings and valuation, EVO or QSI?

Is EVO or QSI more profitable?

Do institutionals and insiders have more ownership in EVO or QSI?

Does the media favor EVO or QSI?

Summary

How does Quantum-Si compare to OmniAb?

Is OABI or QSI more profitable?

Do analysts recommend OABI or QSI?

Does the media favor OABI or QSI?

Which has more risk and volatility, OABI or QSI?

Which has stronger valuation and earnings, OABI or QSI?

Do institutionals & insiders have more ownership in OABI or QSI?

Summary

How does Quantum-Si compare to Cytek Biosciences?

Which has more risk and volatility, CTKB or QSI?

Do analysts prefer CTKB or QSI?

Which has better valuation and earnings, CTKB or QSI?

Is CTKB or QSI more profitable?

Does the media prefer CTKB or QSI?

Do institutionals & insiders hold more shares of CTKB or QSI?

Summary

How does Quantum-Si compare to Ginkgo Bioworks?

Is DNA or QSI more profitable?

Does the media prefer DNA or QSI?

Which has preferable valuation and earnings, DNA or QSI?

Do analysts prefer DNA or QSI?

Which has more risk & volatility, DNA or QSI?

Do institutionals and insiders have more ownership in DNA or QSI?

Summary

How does Quantum-Si compare to Pacific Biosciences of California?

Which has higher earnings and valuation, QSI or PACB?

Do analysts recommend QSI or PACB?

Do institutionals and insiders believe in QSI or PACB?

Which has more volatility & risk, QSI or PACB?

Does the media refer more to QSI or PACB?

Is QSI or PACB more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QSI vs. The Competition

Quantum-Si Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools